利拉鲁肽改善2型糖尿病合并周围血管病变患者经皮氧分压的效果分析  

Effect of Liraglutide on transcutaneous oxygen partial pressure in patients with type 2 diabetes mellitus peripheral vascular disease

作　　者：厚荣荣 尹涛 孔颖[1] 蒋伟[2] 王敏[1] 陈媛[1] 徐静[1] HOU Rongrong;YIN Tao;KONG Ying(Department of Endocrinology,The Second Affiliated Hospital,Xi’an Jiaotong University,Xi’an 710004,China)

机构地区：[1]西安交通大学第二附属医院内分泌科,710004 [2]西安交通大学第二附属医院心血管内科,710004 [3]空军军医大学第一附属医院心血管内科

出　　处：《中国糖尿病杂志》2022年第10期762-765,共4页Chinese Journal of Diabetes

基　　金：国家自然科学基金(82000786);陕西省重点研发计划项目(2020SF-248)。

摘　　要：目的探讨T2DM合并周围血管病变患者使用利拉鲁肽治疗对足背经皮氧分压(TcPO_(2))的影响。方法选取2017年6月至2020年6月于西安交通大学第二附属医院内分泌科治疗的T2DM合并周围血管病变患者99例,分为青年组(<40岁)34例,中年组(40~60岁)44例,老年组(>60岁)21例。在降压、降脂基础上加用利拉鲁肽至少24周,比较各组治疗前后足背TcPO_(2)变化。结果青年、中年组治疗后TcPO_(2)升高,青年组改善更明显(P<0.05)。老年组治疗前后TcPO_(2)无明显变化。结论利拉鲁肽可改善青中年T2DM合并周围血管病变患者下肢微血管灌注。Objective To investigate the effect of Liraglutide on transcutaneous oxygen partial pressure(TcPO_(2))in dorsum of foot in patients with type 2 diabetes mellitus(T2DM)peripheral vascular disease.Methods We retrospectively analyzed the data of 99 patients with T2DM peripheral vascular disease in our department from June 2017 to June 2020.They were divided into young group(<40 years,n=34),middle-aged group(40~60 years,n=44)and elderly group(>60 years,n=21).Patients received antiplatelet therapies,antihypertensive treatmentand lipid-lowering treatment if necessary.Liraglutide was administrated at least for 24 weeks.The changes of TcPO_(2) in dorsum of foot were evaluated.Results After treatment,the levels of TcPO_(2) increased in both young and middle-aged groups,and the improvement was more obvious in the young group(P<0.05).There was no significant change in TcPO_(2) in the elderly group before and after Liraglutide treatment.Conclusion Liraglutide increased the micro vascular perfusion of lower limbs in young and middle-aged patients with T2DM peripheral vascular disease.

关 键 词：糖尿病 2型 周围血管病变 利拉鲁肽 微循环灌注 经皮氧分压 

分 类 号：R587.2[医药卫生—内分泌]